Elisabet de los Pinos net worth and biography

Elisabet de los Pinos Biography and Net Worth

Insider of Aura Biosciences

Eli de los Pinos is the founding CEO of Aura, which she has created from the ground up: She developed the company concept and has spearheaded fundraising efforts, and today, she continues to lead Aura’s strategy and operations. Prior to founding Aura, she worked in Eli Lilly & Co.’s oncology business unit, where she was part of the leadership team responsible for the market launch in Europe of Alimta, a drug for the treatment of lung cancer. Earlier in her career, Eli worked as a post-doctoral fellow at the Institute of Cancer Research in London. She previously completed fellowships at the Mount Sinai School of Medicine Institute of Molecular Medicine and at the Georgetown School of Medicine. Eli holds a Ph.D., magna cum laude, in Molecular Biology from the University of Barcelona and an MBA from IE Business School.

She is a member of the board of overseers at the Museum of Science, Boston. Eli has also been named to Boston Business Journal’s 2009 “Top 40 under 40” list; as a Mass High Tech “Woman to Watch” in 2010; as a “Technology Pioneer” by the World Economic Forum in 2010; and as one of Goldman Sachs’ “100 Most Intriguing Entrepreneurs” in 2014.

What is Elisabet de los Pinos' net worth?: The estimated net worth of Elisabet de los Pinos is at least $3.06 million as of October 29th, 2025. Dr. de los Pinos owns 474,391 shares of Aura Biosciences stock worth more than $3,059,822 as of December 4th. This net worth evaluation does not reflect any other assets that Dr. de los Pinos may own. Additionally, Dr. de los Pinos receives an annual salary of $795,300.00 as Insider at Aura Biosciences. Learn More about Elisabet de los Pinos' net worth.
How old is Elisabet de los Pinos?: Dr. de los Pinos is currently 51 years old. There are 1 older executives and no younger executives at Aura Biosciences. Learn More on Elisabet de los Pinos' age.
What is Elisabet de los Pinos' salary?: As the Insider of Aura Biosciences, Inc., Dr. de los Pinos earns $795,300.00 per year. Learn More on Elisabet de los Pinos' salary.
How do I contact Elisabet de los Pinos?: The corporate mailing address for Dr. de los Pinos and other Aura Biosciences executives is , , . Aura Biosciences can also be reached via phone at 617-500-8864 and via email at [email protected]. Learn More on Elisabet de los Pinos' contact information.
Has Elisabet de los Pinos been buying or selling shares of Aura Biosciences?: Within the last three months, Elisabet de los Pinos has sold $57,461.15 in shares of Aura Biosciences stock. Most recently, Los Pinos Elisabet De sold 9,049 shares of the business's stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $6.35, for a transaction totalling $57,461.15. Following the completion of the sale, the insider now directly owns 474,391 shares of the company's stock, valued at $3,012,382.85. Learn More on Elisabet de los Pinos' trading history.
Who are Aura Biosciences' active insiders?: Aura Biosciences' insider roster includes Elisabet de los Pinos (Insider), Amy Elazzouzi (SVP), Anthony Gibney (Insider), Janet Hopkins (Chief Medical Officer and President of Research & Development), David Johnson (Director), Conor Kilroy (Insider), and Mark Plavsic (CTO). Learn More on Aura Biosciences' active insiders.
Are insiders buying or selling shares of Aura Biosciences?: In the last twelve months, Aura Biosciences insiders bought shares 2 times. They purchased a total of 70,000 shares worth more than $343,000.00. In the last twelve months, insiders at the sold shares 13 times. They sold a total of 79,568 shares worth more than $514,201.11. The most recent insider tranaction occured on November, 17th when insider Janet Jill Hopkins sold 17,109 shares worth more than $92,730.78. Insiders at Aura Biosciences own 6.3% of the company. Learn More about insider trades at Aura Biosciences.
Information on this page was last updated on 11/17/2025.

Elisabet de los Pinos Insider Trading History at Aura Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/29/2025	Sell	9,049	$6.35	$57,461.15	474,391
1/21/2025	Sell	15,955	$7.67	$122,374.85	304,692
10/29/2024	Sell	9,200	$10.74	$98,808.00	320,647
10/18/2024	Sell	24,992	$12.04	$300,903.68	329,847
1/23/2024	Sell	15,853	$7.64	$121,116.92	161,438
11/6/2023	Sell	7,449	$12.03	$89,611.47	177,291
10/30/2023	Sell	9,586	$6.83	$65,472.38	180,940

Elisabet de los Pinos Buying and Selling Activity at Aura Biosciences

Aura Biosciences Company Overview

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $6.45

$6.21

$6.53

50 Day Range

MA: $5.92

$5.35

$6.61

2 Week Range

Now: $6.45

$4.34

$9.14

Volume

117,755 shs

Average Volume

200,153 shs

Market Capitalization

$409.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.44

Elisabet de los Pinos Biography and Net Worth

What is Elisabet de los Pinos' net worth?

How old is Elisabet de los Pinos?

What is Elisabet de los Pinos' salary?

How do I contact Elisabet de los Pinos?

Has Elisabet de los Pinos been buying or selling shares of Aura Biosciences?

Who are Aura Biosciences' active insiders?

Are insiders buying or selling shares of Aura Biosciences?